Sharma R P, Javaid J I, Faull K, Davis J M, Janicak P G
Department of Psychiatry, University of Illinois at Chicago.
Psychiatry Res. 1994 Jan;51(1):51-60. doi: 10.1016/0165-1781(94)90046-9.
The authors report a significant positive correlation between levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) in cerebrospinal fluid (CSF) and plasma in drug-free affective disorder patients (major depression, mania, and schizoaffective disorder), but not in schizophrenia. Recent kinetic studies on the relationship between plasma and CSF MHPG discourage the interpretation of independent CSF MHPG levels without correction for the diffusion of MHPG across the blood-brain barrier. The authors therefore examine pretreatment CSF and plasma MHPG levels, and the CSF MHPG index (CSF MHPG corrected for by using simultaneously obtained plasma MHPG according to the method of Kopin et al. [1983]). No significant differences were found in these pretreatment MHPG measures among the four diagnostic groups. Changes in these MHPG indices, and their correlations with behavioral rating scores, are also examined with respect to response to the four major somatic therapies (neuroleptics, lithium, antidepressants, and electroconvulsive therapy).
作者报告称，在未服用药物的情感障碍患者（重度抑郁症、躁狂症和分裂情感性障碍）中，脑脊液（CSF）和血浆中3-甲氧基-4-羟基苯乙二醇（MHPG）水平之间存在显著正相关，但在精神分裂症患者中则不存在。最近关于血浆和脑脊液MHPG之间关系的动力学研究不支持在未校正MHPG通过血脑屏障扩散的情况下对独立的脑脊液MHPG水平进行解释。因此，作者检测了治疗前脑脊液和血浆中的MHPG水平，以及脑脊液MHPG指数（根据Kopin等人[1983年]的方法，用同时获得的血浆MHPG校正后的脑脊液MHPG）。在这四个诊断组的这些治疗前MHPG测量值中未发现显著差异。还针对四种主要躯体疗法（抗精神病药、锂盐、抗抑郁药和电休克疗法）的反应，研究了这些MHPG指数的变化及其与行为评分的相关性。
